CA2238271A1 - Pharmaceutical compositions comprising flurbiprofen - Google Patents

Pharmaceutical compositions comprising flurbiprofen

Info

Publication number
CA2238271A1
CA2238271A1 CA002238271A CA2238271A CA2238271A1 CA 2238271 A1 CA2238271 A1 CA 2238271A1 CA 002238271 A CA002238271 A CA 002238271A CA 2238271 A CA2238271 A CA 2238271A CA 2238271 A1 CA2238271 A1 CA 2238271A1
Authority
CA
Canada
Prior art keywords
flurbiprofen
pharmaceutical compositions
treatment
sore
masticable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002238271A
Other languages
French (fr)
Other versions
CA2238271C (en
Inventor
David Michael Barrett
Carl Simon Smith
David Michael Thurgood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reckitt Benckiser Healthcare UK Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2238271A1 publication Critical patent/CA2238271A1/en
Application granted granted Critical
Publication of CA2238271C publication Critical patent/CA2238271C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to the use of flurbiprofen in the treatment of sore throats which comprises the administration to a patient in need of such treatment of a pharmaceutical composition in the form of a masticable or suckable solid dosage form or a spray containing a therapeutically effective amount of flurbiprofen which releases the flurbiprofen in the oral cavity so as to deliver the flurbiprofen to the surface of the sore throat.
CA002238271A 1995-11-22 1996-11-21 Pharmaceutical compositions comprising flurbiprofen Expired - Fee Related CA2238271C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9523833.3 1995-11-22
GBGB9523833.3A GB9523833D0 (en) 1995-11-22 1995-11-22 Medical treatment
PCT/EP1996/005208 WO1997018802A1 (en) 1995-11-22 1996-11-21 Pharmaceutical compositions comprising flurbiprofen

Publications (2)

Publication Number Publication Date
CA2238271A1 true CA2238271A1 (en) 1997-05-29
CA2238271C CA2238271C (en) 2008-08-12

Family

ID=10784245

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002238271A Expired - Fee Related CA2238271C (en) 1995-11-22 1996-11-21 Pharmaceutical compositions comprising flurbiprofen

Country Status (21)

Country Link
US (2) US5889057A (en)
EP (1) EP0862424B1 (en)
CN (1) CN1148177C (en)
AT (1) ATE252382T1 (en)
AU (1) AU707749B2 (en)
BG (1) BG64166B1 (en)
CA (1) CA2238271C (en)
CZ (1) CZ289643B6 (en)
DE (1) DE69630460T2 (en)
DK (1) DK0862424T3 (en)
ES (1) ES2208768T3 (en)
GB (1) GB9523833D0 (en)
HU (1) HU225235B1 (en)
IL (1) IL124568A0 (en)
NO (1) NO317287B1 (en)
NZ (1) NZ322933A (en)
PT (1) PT862424E (en)
RU (1) RU2203655C2 (en)
SK (1) SK284092B6 (en)
UA (1) UA46807C2 (en)
WO (1) WO1997018802A1 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9523833D0 (en) * 1995-11-22 1996-01-24 Boots Co Plc Medical treatment
GB9710521D0 (en) * 1997-05-22 1997-07-16 Boots Co Plc Process
AU7916798A (en) * 1997-05-22 1998-12-11 Boots Company Plc, The Pharmaceutical compositions of flurbiprofen and burn-masking agent for treating sore throat
WO1998052540A1 (en) * 1997-05-22 1998-11-26 The Boots Company Plc Pharmaceutical compositions
AU779783B2 (en) * 1999-05-17 2005-02-10 Eisai Inc. Improved cellular uptake of bioactive agents
JP2003530437A (en) * 2000-04-13 2003-10-14 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ Aβ42 lowering substance
WO2003041705A1 (en) * 2001-11-13 2003-05-22 Pharmacia Corporation Oral dosage form of a sulfonamide prodrug such as parecoxib
US20090035260A1 (en) * 2002-07-29 2009-02-05 Therapicon Srl Enhanced nasal composition of active peptide
ES2405287T3 (en) * 2002-08-01 2013-05-30 Eisai Inc. Improved treatment of glutamine cancer
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc Method and composition for treating neurodegenerative disorders
US20040265359A1 (en) * 2003-04-17 2004-12-30 Sacks Gordon S. Oral delivery formulations of L-glutamine
WO2005065069A2 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
FR2865648B1 (en) * 2004-02-03 2006-06-30 Philippe Perovitch METHOD FOR DIFFUSION OF INSOLUBLE MOLECULES IN AQUEOUS MEDIUM AND COMPOSITION IMPLEMENTING SAID METHOD
ITMI20040235A1 (en) * 2004-02-13 2004-05-13 Therapicon Srl PHARMACEUTICAL PREPARATION FOR THE ORAL CABLE
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
US20050252144A1 (en) * 2004-04-29 2005-11-17 Macdonald Robert A Veneers for walls, retaining walls and the like
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
BRPI0514303A (en) * 2004-08-11 2008-06-10 Myriad Genetics Inc pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
GB2423710A (en) 2005-03-01 2006-09-06 Boots Healthcare Int Ltd Lozenge production process
JP2009502807A (en) * 2005-07-22 2009-01-29 ミリアド ジェネティクス， インコーポレイテッド Formulations and dosage forms with high drug content
WO2007055887A1 (en) * 2005-11-02 2007-05-18 Teikoku Pharma Usa, Inc. Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same
US7282224B1 (en) * 2006-06-09 2007-10-16 Guthy-Renker Corporation Pain relief composition
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
US7754234B2 (en) * 2006-07-12 2010-07-13 Jones Thomas L Composition and method of treating a sore throat
US20080107747A1 (en) * 2006-10-23 2008-05-08 Roederer Joy E Pain relief composition
BRPI0809430A2 (en) * 2007-07-23 2014-09-09 Teikoku Pharma Usa Inc ORGANOLEPTICALLY ACCEPTABLE ORAL FORMULATIONS OF AN INDOL CEROTONIN RECEIVER AGONIST AND METHODS OF USE
MX2011012315A (en) 2009-05-19 2011-12-16 Neuroderm Ltd Compositions for continuous administration of dopa decarboxylase inhibitors.
IT1397132B1 (en) 2009-12-01 2013-01-04 Alfa Wassermann Spa COMPOSITIONS INCLUDING NON-STEROID ANTI-INFLAMMATORS.
ES2660772T3 (en) * 2010-11-15 2018-03-26 Neuroderm Ltd Continuous administration of L-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions therefor
GB201021267D0 (en) * 2010-12-15 2011-01-26 Reckitt Benckiser Healthcare Int Ltd Novel pharmaceutical formulation
PL2854764T3 (en) 2012-06-05 2019-07-31 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
GB201216893D0 (en) 2012-09-21 2012-11-07 Aesica Pharmaceuticals Ltd Drug substance preparations, pharmaceutical compositions and dosage forms comprising s-(+)-flurbiprofen
PT3116475T (en) 2014-03-13 2020-12-15 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
CN110812331A (en) * 2018-08-10 2020-02-21 北京普德康利医药科技发展有限公司 Flurbiprofen pharyngeal retention particle
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1062721A (en) * 1975-12-15 1979-09-18 Anthony A. Sinkula Propionic acid derivatives
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
JPH0647532B2 (en) * 1983-08-31 1994-06-22 ジ アツプジヨン カンパニ− Treatment of alveolar bone resorption
AU6656886A (en) * 1985-12-16 1987-06-18 Cilag A.G. Pharmaceutical composition of suprofen
EP0321505A1 (en) * 1986-10-22 1989-06-28 The Upjohn Company Treatment of gingivitis with ibuprofen or flurbiprofen
JPS63156715A (en) * 1986-12-19 1988-06-29 Teisan Seiyaku Kk Quick-acting slowly releasing agent
JP2540581B2 (en) * 1988-02-04 1996-10-02 三省製薬株式会社 Topical
US4931473A (en) * 1989-02-15 1990-06-05 Richardson-Vicks Inc. Anesthetic oral compositions
DE69016665T3 (en) * 1989-08-17 1999-01-14 Sepracor Inc ORAL S (+) - MEDIUM CONTAINING FLURBIPROFEN OR KETOPROFEN.
US5190981A (en) * 1989-08-17 1993-03-02 Sepracor Inc. Formulation containing S(+) enantiomer of flurbiprofen or ketoprofen and method of use for oral administration for prevention and treatment of bone loss associated with periodontal disease
JP2738092B2 (en) * 1989-11-17 1998-04-08 ライオン株式会社 Oral composition
JPH0426618A (en) * 1990-05-21 1992-01-29 Japan Tobacco Inc Troche
IT1243342B (en) * 1990-07-13 1994-06-10 Farcon Ag ORAL PHARMACEUTICAL COMPOSITIONS FOR LIQUID ANTI-INFLAMMATORY ACTIVITIES
DE4028906A1 (en) * 1990-09-12 1992-03-19 Paz Arzneimittelentwicklung MEDICINAL PRODUCTS AND THEIR PREPARATION AND THEIR USE IN THE CONTROL OF PAIN AND / OR DEFENSE AND / OR FEVER OF ANIMALS AND PEOPLE
WO1994013280A1 (en) * 1992-12-04 1994-06-23 Mayor Pharmaceutical Laboratories, Inc. Sprayable analgesic composition and method of use
WO1994014476A1 (en) * 1992-12-21 1994-07-07 The Procter & Gamble Company Use of s(+) antipodes of analgesic agents for the manufacture of a composition to treat respiratory disorders
US5458879A (en) * 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
ES2211916T3 (en) * 1994-09-02 2004-07-16 Virginia Commonwealth University COMPOSITION TO RELIEF PAIN, CONTAINING A NON-NARCORTIC ANALGESIC AND AN ANALGESIC POTENTIATOR.
US5567733B1 (en) * 1995-04-27 1999-08-24 Jon G Dishler Irritation relief using nonsteroidal anti-inflammatory compounds
JPH11508593A (en) * 1995-07-05 1999-07-27 ザ、プロクター、エンド、ギャンブル、カンパニー Heating compound
GB9523833D0 (en) * 1995-11-22 1996-01-24 Boots Co Plc Medical treatment
US5955098A (en) * 1996-04-12 1999-09-21 Flemington Pharmaceutical Corp. Buccal non polar spray or capsule
ES2234010T3 (en) * 1996-04-12 2005-06-16 Novadel Pharma Inc. POLAR ORAL SPRAY.

Also Published As

Publication number Publication date
SK66598A3 (en) 1998-12-02
RU2203655C2 (en) 2003-05-10
BG64166B1 (en) 2004-03-31
US5889057A (en) 1999-03-30
EP0862424B1 (en) 2003-10-22
GB9523833D0 (en) 1996-01-24
BG102526A (en) 1999-02-26
IL124568A0 (en) 1998-12-06
CN1207677A (en) 1999-02-10
NZ322933A (en) 2000-02-28
WO1997018802A1 (en) 1997-05-29
PT862424E (en) 2004-02-27
CN1148177C (en) 2004-05-05
DE69630460D1 (en) 2003-11-27
HUP0000180A3 (en) 2001-10-29
EP0862424A1 (en) 1998-09-09
ES2208768T3 (en) 2004-06-16
DK0862424T3 (en) 2003-12-29
NO317287B1 (en) 2004-10-04
DE69630460T2 (en) 2004-08-19
US6166083A (en) 2000-12-26
HUP0000180A2 (en) 2000-08-28
AU707749B2 (en) 1999-07-22
HU225235B1 (en) 2006-08-28
CZ156598A3 (en) 1998-08-12
NO982294L (en) 1998-07-20
CA2238271C (en) 2008-08-12
ATE252382T1 (en) 2003-11-15
NO982294D0 (en) 1998-05-20
CZ289643B6 (en) 2002-03-13
SK284092B6 (en) 2004-09-08
UA46807C2 (en) 2002-06-17
AU2611997A (en) 1997-06-11

Similar Documents

Publication Publication Date Title
CA2238271A1 (en) Pharmaceutical compositions comprising flurbiprofen
RU98111594A (en) PHARMACEUTICAL COMPOSITIONS INCLUDING FLURBIPROFEN
CA2110313A1 (en) Pharmaceutical compositions containing a guanidinothiazole compound and antacids
AU3731699A (en) Orally disintegrable tablets
EP1674107B8 (en) Use of daptomycin
CA2105180A1 (en) Compositions containing sumatriptan
CA2124677A1 (en) Immunopotentiatory agents and physiologically acceptable salts thereof
CA2214097A1 (en) Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx
IL103303A (en) Pharmaceutical compositions containing ibuprofen and codeine for relief of chronic pain
CA2004239A1 (en) Use of acetyl d-carnitine in the therapeutic treatment of glaucoma, and pharmaceutical compositions useful in such treatment
CA2419993A1 (en) Process for preparing pharmaceutical compositions for use with soft gelatin formulations
IL108234A0 (en) Pharmaceutical composition containing galanthamine
CA2143413A1 (en) Local Drug Delivery Film, for Periodontal Treatment
CA2038744A1 (en) Pharmaceutical composition containing slightly water-soluble drug
CA2318260A1 (en) Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis
ATE187334T1 (en) PHARMACEUTICAL COMPOSITION IN THE FORM OF A GEL CONTAINING CHONDROITIN SULFATE IN SALT FORM FOR ORAL ADMINISTRATION
GR3032041T3 (en) Idebenone compositions for treating Alzheimer's disease.
CA2279184A1 (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
NZ332655A (en) Pharmaceutical compositions containing diclofenac and alkali metal bicarbonates
BR0014440A (en) Oral controlled release formulations
CA2077693A1 (en) Use of ketorolac for treatment of periodontal disease
EG17992A (en) Preparation of a medicament for arthritis and theumatism
EP0272393A3 (en) Pharmaceutical combination
CA2173839A1 (en) Transferrin compositions to alleviate the side effects of cytotoxic drugs
HK1016867A1 (en) Bismuth-containing compositions in topical dosage forms

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20151123

MKLA Lapsed

Effective date: 20151123